A b s t r a c t
It is unclear how often and in what setting fluorescence in situ hybridization (FISH) panels for myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) provide additional information over metaphase cytogenetics alone. Furthermore, the usefulness of peripheral blood vs bone marrow FISH has also not been directly compared. We prospectively compared metaphase cytogenetics and FISH for -5/5q-, -7/7q-, +8, and 20q-in 433 cases of suspected MDS/AML. FISH testing was abnormal in 6 (14%) of 43 and 10 (19%) of 54 cases with fewer than 20 normal metaphases or no growth, respectively. FISH was only rarely abnormal in cases with 20 normal metaphases obtained (6/222 [2.7%]). Comparison of peripheral blood and bone marrow results in 48 cases showed abnormal peripheral blood FISH results in 18 (69%) of 26 cases with abnormal bone marrow FISH results and in 5 (23%) of 22 cases with normal bone marrow FISH results. These findings, the largest published comparison of FISH vs metaphase cytogenetics in MDS/AML, provide a rational strategy for FISH testing in peripheral blood and bone marrow.
Cytogenetic information is essential to the diagnosis, classification, and prognostic assessment of myelodysplastic syndromes (MDSs) and acute myeloid leukemia (AML). 1, 2 Traditionally, this information could be obtained only from metaphase cytogenetic studies. Increasingly, many laboratories also perform interphase fluorescence in situ hybridization (FISH) studies for MDS-associated cytogenetic abnormalities, usually with a panel of probes designed to detect -5/5q-, -7/7q-, +8, and 20q-. However, the clinical usefulness of FISH studies and the settings in which FISH might provide information that is not obtained by metaphase cytogenetics alone remain uncertain. Prior studies that compare metaphase cytogenetics and FISH panel testing in MDS have yielded conflicting results. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] These reports are largely retrospective, include relatively few cases, and are usually restricted to patients with a definitive diagnosis of MDS before FISH testing. Most reports describe results of bone marrow samples, but FISH analysis of peripheral blood samples offers the potential for noninvasive screening for MDS-associated cytogenetic abnormalities before bone marrow examination and monitoring the size of the clone in patients undergoing therapy. The diagnostic yield of peripheral blood vs bone marrow FISH studies has not been previously examined in MDS.
To determine the additional value of FISH panel testing over metaphase cytogenetics alone and to compare the usefulness of peripheral blood vs bone marrow FISH, we prospectively compared metaphase karyotyping and FISH panel testing in 433 bone marrow specimens submitted to our laboratory for a clinical suspicion of MDS or AML. In 48 cases, we compared results of peripheral blood-and bone Upon completion of this activity you will be able to:
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Questions appear on p 976. Exam is located at www.ascp.org/ajcpcme. For cases analyzed at the Cleveland Clinic, FISH studies were performed as previously described, 13 using the following probes: LSI EGR1 SpectrumOrange (5q31)/D5S23, D5S721 SpectrumGreen, LSI D7S486 SpectrumOrange (7q31)/CEP7 SpectrumGreen, CEP8 SpectrumGreen, and LSI D20S108 SpectrumOrange (20q12) (Abbott Molecular, Abbott Park, IL). Briefly, cytogenetic cell pellets (bone marrow) or gravity preparations (peripheral blood) were fixed in Carnoy solution, washed, and subjected to Proteinase K treatment. Following wash treatment, a 10-μL probe solution was applied, and probe and target DNA was allowed to codenature at 73°C for 5 minutes and hybridize overnight at 37°C. Slides were counterstained with 4',6-diamidino-2-phenylindole (DAPI), and signals were visualized on an Axioskop photomicroscope (Zeiss, Oberkochen, Germany). We counted 200 interphase nuclei. Normal ranges were established by analysis of 10 normal bone marrow cytogenetic pellets and 10 peripheral blood samples, yielding cutoffs of 6%, 6%, 7%, 5%, 4%, and 9% for -5, 5q-, -7, 7q-, +8, and 20q-, respectively. For cases analyzed at the outside reference laboratory, similar cutoffs of 4%, 6%, 4.5%, 6.5%, 1.5%, and 4.5% were used. FISH results were interpreted by the molecular pathology staff independent of concurrent metaphase karyotyping.
FISH Analysis

Metaphase Cytogenetics
Bone marrow metaphase cytogenetic studies were performed at the Cleveland Clinic in all cases according to standard methods. Chromosome preparations were G-banded using trypsin and Giemsa, and karyotypes were described according to the International System for Human Cytogenetic Nomenclature. 14 
Results
Metaphase cytogenetics and FISH testing for -5/5q-, -7/7q-, +8, and 20q-were performed in 433 bone marrow samples obtained for clinically suspected MDS or AML. Overall, an abnormal karyotype was identified in 114 cases (26.3%), and abnormal FISH results for at least 1 locus were obtained in 94 cases (21.7%). The combined diagnostic yield for an abnormal result by FISH or metaphase cytogenetics was 136 (31.4%) of 433. Of the 136 cases with any abnormal finding, 22 (16.2%) were identified only by FISH.
As summarized in ❚Table 1❚, the additional diagnostic yield of FISH over metaphase cytogenetics alone varied with the number of metaphase cells available for analysis. In cases with at least 20 normal metaphase cells, abnormal FISH findings were obtained in only 6 (2.7%) of 222 cases ❚Table 2❚. These cases included 1 bone marrow involved by myeloma with trisomy 5 and trisomy 8 that was likely in plasma cells rather than in myeloid cells and 5 cases with abnormal FISH patterns found in 10% or fewer nuclei. In contrast, abnormal FISH findings were found in 6 (14%) of 43 and 10 (19%) of 54 cases with suboptimal growth (<20 normal metaphases identified) or with no growth, respectively.
In cases with an abnormal karyotype by metaphase cytogenetics, at least 1 locus in the FISH panel was abnormal in 72 (63.2%) of 114 cases. Overall, results of metaphase cytogenetics and FISH were concordant in 96.5%, 96.5%, 93.9%, and 93.0% of cases for abnormalities of chromosomes 5, 7, 8, and 20, respectively. ❚Table 3❚ shows the 20 cases with apparently discrepant results between metaphase cytogenetics and FISH studies at 1 or more loci. These 20 cases included 7 that contained marker or ring chromosomes of uncertain derivation and 11 cases characterized by relatively small additional clones (<20% of interphase nuclei) detected by FISH but not by metaphase cytogenetics. Among the 37 cases with abnormal karyotypes that did not involve chromosomes 5, 7, 8, or [5] 44-47,XY,add(3)(p12) [15] ,+add(3)(p12) [4] ,-5 [6] ,del(5)(q12q33) [9] ,add(6)(p25) [6] ,+8 [14] , P 5q-(38) N P (34) N * +8 [2] ,-17 [15] ,-20 [15] ,+22 [5] ,+mar [11] ,+mar [2] [cp15]/46,XY [5] 46,XY,del (5) P 5q-(10) N P (2) * N 47,XX,del(7)(q31),+8 [3] /47,idem,del(3)(q22) [17] N P 7q-(74) P (50) P (15) * 49,XX,-7,+8,+8,+9,+13 [6] /46,XX [14] N N * N * N 45-49,XY,+1,der(1;7)(q10;p10),+8 [3] ,+9 [3] ,+22 [2] [cp5]/46,XY [15] N P 7q-(10) N * P (4) * 45-46,XX,add(1)(p36.3),del(5)(q14),-7,-11,der(12)t(7;12)(p13;p13),-13, P 5q-(25) P 7q-(33) N N * add (13) [11] /46,XY [9] P 5q-(15) * N N N 47,Y,t(X;1)(p22.1;q25) [12] ,add(3)(p26) [10] ,del(4)(q21) [9] ,del(5)(q13q31) [4] , N * P 7q-(19) P (18) P (26) del (7) [1] [cp2] 46,XY,?add(7)(q22) or ?del(7)(q22q22) [5] /46,XX [15] N N * N N 46,XY,del(3)(p14),del(5)(q31q35),del(9)(q12q22),del(11)(q13q22),add(12)(p13), N * N N N t(13;19)(q12;q13) [3] 43-45,XY,del(3)(p12p21) [8] ,-5 [16] ,-7 [10] ,add(11)(q13) [10] ,ins(12;?)(q13;?) [11] , P 5q-(22) P -7 (26) N N * -14 [9] ,+16 [8] ,-20 [13] ,add(21)(p11.2) [12] ,+21 [3] +1-3mar [15] [cp17]/46,XY [3] FISH, fluorescence in situ hybridization; N, negative; P, positive. * Discrepant results.
† Numbers in parentheses are percentages.
of peripheral blood FISH studies were normal. The size of the largest abnormal FISH clone noted in the bone marrow was smaller in cases with normal peripheral blood studies than in cases with abnormal peripheral blood findings (mean ± SEM, 17% ± 11% vs 49% ± 6.9%; P = .007; unpaired Student t test). Of 22 cases with normal bone marrow FISH results, 17 (77%) had normal peripheral blood FISH results, and 5 cases (23%) had abnormal peripheral blood findings. The morphologic findings in the 5 cases with abnormal FISH results only in the peripheral blood were reviewed, and the details of these cases are shown in ❚Table 5❚. Each of these cases showed morphologic evidence of an MDS in the bone marrow and a relatively small percentage of abnormal nuclei in the peripheral blood (≤20%). The size of the largest abnormal FISH clone noted in the peripheral blood was larger in cases with abnormal bone marrow FISH results than in cases with normal bone marrow FISH results (mean ± SEM, 50% ± 7% vs 16% ± 2%; P = .018; unpaired Student t test).
Discussion
Metaphase cytogenetic analysis has long been an integral part of the evaluation of suspected myeloid malignancies, and cytogenetic data have a direct role in the classification of such neoplasms by current World Health Organization criteria. 1, 15 Metaphase cytogenetics alone, however, may be noninformative when insufficient numbers of metaphase cells are obtained for examination owing to a hypocellular specimen or absent or suboptimal growth in culture. Similarly, some diagnostically significant abnormalities, such as subtle MLL rearrangements in MDS/AML or FIP1L1-PDGFRA fusion in eosinophilic myeloproliferative neoplasms, may be cryptic by metaphase cytogenetics. 16, 17 FISH studies offer the opportunity to supplement standard banded karyotyping by detecting abnormalities in interphase nuclei and clarifying cryptic or complex abnormalities. FISH studies also have limitations, however. 18, 19 That there are many common genetic abnormalities in MDS/AML requires that multiple FISH probes be scored, leading to increased technologist time and expense. Furthermore, abnormalities that are not specifically targeted by the probes in the panel will remain undetectable if FISH studies are the only mode of analysis. Although several relatively small prior studies [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] have compared FISH with metaphase cytogenetics in MDS, results are conflicting, and the most cost-and labor-efficient use of FISH as a supplement to metaphase cytogenetics remains uncertain.
In this study, which is the largest reported comparison of metaphase cytogenetics and MDS FISH panel testing to date, we identified abnormal FISH findings in 94 (21.7%) of 433 cases, including 6 (14%) of 43 cases with fewer than 20 available metaphase cells (suboptimal growth) and 10 (19%) of 54 cases with no growth. In contrast, in cases with a normal result in 20 or more metaphase cells, FISH studies were positive in only 6 (2.7%) of 222 cases. Of these 6 cases, 1 involved a patient with relapsed myeloma and suspected MDS in which FISH showed +5 and +8. Given that +5 is common in myeloma 20 and rare in MDS, these abnormalities are likely representative of plasma cells rather than myeloid elements. The 5 remaining cases with a normal karyotype and abnormal FISH results each showed 10% or fewer abnormal nuclei. Because, by definition, numeric (gain) or structural abnormalities must be identified in at least 2 metaphase cells to be considered clonal by cytogenetics, these small clones would be at or below the sensitivity of a standard cytogenetic study in which only 20 metaphase cells are routinely analyzed. A sufficient number of follow-up cytogenetic studies was not available to assess the significance of such small clones that were detected by FISH only.
In contrast with earlier, smaller studies suggesting that FISH panel testing may identify additional abnormalities in up to 17% of cases with at least 20 normal metaphase cells, 3,9,10 our findings are similar to the findings of recent studies of more than 100 cases that also found that FISH studies added little to the diagnostic yield of adequate metaphase cytogenetics alone. 8, 21 For example, Pitchford et al 21 found that FISH panel testing provided additional information in only 1 of 102 MDS cases with 20 or more metaphase cells. It is important to note that prior studies have been restricted to retrospective analyses of cases with definitive morphologic or cytogenetic evidence of an MDS before FISH testing. In this series, we prospectively studied all bone marrow cases submitted to our laboratory for MDS FISH testing for clinically suspected MDS. This approach allows for potential inclusion of morphologically subtle MDS cases in which a presumptive diagnosis of MDS might be made on the basis of abnormal FISH testing alone. Our results indicate that the diagnostic yield of FISH over adequate metaphase cytogenetics in this population is also very small. These findings indicate that G-banded karyotyping alone is sufficient as an initial evaluation of suspected MDS/AML. MDS FISH panel testing should be reserved for cases with suboptimal growth or when clarification of an abnormal karyotype is indicated.
Among cases with an abnormal karyotype by cytogenetics, FISH panel testing was abnormal in 72 (63.2%) of 114 cases. This detection rate is similar to the yield of 68% to 80% noted in prior studies using a similar probe panel. 12, 21 FISH and metaphase cytogenetic results in these karyotypically abnormal cases were concordant in more than 90% of cases for each locus, and many of these potential discrepancies seemed to be due to the presence of marker or ring chromosomes that could not be definitively characterized by G-banding or to small subclones found only by FISH that were quantitatively beneath the detection threshold of a routine cytogenetic study. Because demonstration of 5q or chromosome 7 abnormalities has important therapeutic and prognostic implications, FISH testing may be clinically useful to clarify subtle changes in cases with an abnormal G-banded karyotype. Among the cases with an abnormal karyotype but normal chromosomes 5, 7, 8, and 20, the most common recurrent abnormality involved 3q26. The addition of a break-apart probe for EVI1 (3q26) to the FISH panel would theoretically increase the detection rate to 75% of abnormal cases in this series.
Although previous studies have examined the peripheral blood of patients with MDS for evidence of clonality using several techniques, including FISH, 22, 23 this is the first study to directly compare the usefulness of routine FISH panel testing in peripheral blood vs bone marrow. Overall, abnormal peripheral blood FISH results were seen in 18 (69%) of 26 cases with bone marrow FISH abnormalities. Because clinical data were not available for all cases, it is possible that some patients were treated between the peripheral blood and bone marrow analyses. Cases with abnormal bone marrow FISH but normal peripheral blood FISH results tended to have small neoplastic clones in the bone marrow. These results indicate that peripheral blood FISH testing may be useful for initial noninvasive evaluation of patients with cytopenias and suspected MDS. Although peripheral blood FISH testing is limited by a relatively high false-negative rate (31%) and bone marrow aspirate and biopsy findings remain necessary for classification of MDS, the demonstration of an abnormal FISH result provides easily (noninvasively) obtained data that may aid clinical decision making with respect to the appropriate time to perform a bone marrow evaluation vs continuing a "watch and wait" period.
It is interesting that 5 (23%) of 22 cases with normal bone marrow FISH studies had abnormal peripheral blood FISH results, which also tended to be relatively small clones compared with those in cases with abnormal findings in both the peripheral blood and bone marrow. The significance of these small abnormal clones in the peripheral blood only remains uncertain. It is possible that such small clones might be masked in the bone marrow by an increased number of nonneoplastic erythroid elements, lymphoid cells, or plasma cells, while analysis of the predominantly myeloid elements in the peripheral blood might allow for easier identification of this smaller abnormal population. Additional follow-up will be needed to determine the significance of low numbers of abnormal cells that are detected in the peripheral blood only. Finally, this study does not provide a direct comparison of peripheral blood metaphase cytogenetics with peripheral blood FISH because cytogenetic studies of unstimulated peripheral blood and absent or low numbers of spontaneously dividing cells are known to have a higher failure rate compared with bone marrow.
This study shows that FISH panel testing allows for sensitive detection of chromosomal abnormalities that may alter the diagnosis, classification, or prognostic assessment in cases of clinically known or suspected MDS/AML. However, such studies offer little, if any, additional information when a normal karyotype is found by an adequate (≥20 metaphase cells) bone marrow cytogenetic study. FISH panels are, therefore, best used in the setting of suboptimal growth in metaphase cytogenetics or when an abnormal karyotype is obtained and there is a clinical need to clarify the karyotypic findings at specific loci.
Our laboratory currently performs more than 400 MDS FISH panel tests a year. Eliminating routine FISH panel testing in cases with an adequate number of analyzed cells and a normal karyotype would decrease bone marrow FISH testing by 51%. Peripheral blood FISH testing provides a useful noninvasive technique for the detection of cytogenetic abnormalities in patients with suspected disease, although a normal peripheral blood FISH result clearly does not exclude the possibility of disease. The ability to serially monitor an abnormal clone in the peripheral blood may allow for less frequent follow-up bone marrow evaluations. These results provide a rational strategy for effective use of MDS FISH panel testing in the bone marrow and peripheral blood.
